Amendment to the Claims. Please amend claims 1, 18 and 19, cancel claims 15 and 16, without prejudice, and add new claims 32-38 as follows.

Listing of the Claims. This listing replaces any previous listing.

1 (Currently amended). A method for treating an inflammatory response in the ~~gastrointestinal tract~~ small intestine, of a subject ~~by modulating physiology or development of a macrophage cell expressing a receptor for a TECK polypeptide, which polypeptide comprises the amino acid sequence set forth in Gln1 to Leu127 of SEQ ID NO: 4~~, comprising administering ~~contacting the cell with~~ an antagonist antibody or an antigen-binding fragment thereof that binds specifically to an epitope in a polypeptide which epitope consists of amino acids Gln1 to Leu127 of SEQ ID NO: 4, to said subject ~~the polypeptide~~.

2-17 (Cancelled).

18 (Currently amended). The method of Claim 1 wherein the ~~gastrointestinal inflammation~~ inflammatory response is Crohn's disease.

19 (Currently amended). The method of Claim 1 wherein the ~~gastrointestinal inflammation~~ inflammatory response is inflammatory bowel disease.

20-21 (Cancelled).

22 (Previously presented). The method of Claim 1 wherein the antibody or antigen-binding fragment is conjugated to a chemical moiety.

23 (Currently amended). The method of Claim 1 wherein ~~the antigen-binding~~ said antibody or fragment is a fragment and the fragment is a Fv fragment.

24 (Currently amended). The method of Claim 1 wherein said antibody or fragment is a ~~the antigen-binding~~ fragment and the fragment is a Fab fragment.

25 (Currently amended). The method of Claim 1 wherein said antibody or fragment is a ~~the antigen-binding~~ fragment and the fragment is a Fab2 fragment.

26 (Currently amended). The method of Claim 1 wherein said antibody or fragment is an antibody and the antibody is a monoclonal antibody.

27 (Currently amended). The method of Claim 1 wherein said antibody or fragment is an antibody and the antibody is a polyclonal antibody.

28 (Previously presented). The method of Claim 1 wherein the antibody or antigen-binding fragment exhibits a Kd greater than 300 μM to the TECK polypeptide.

29 (Previously presented). The method of Claim 1 wherein the antibody or antigen-binding fragment exhibits a Kd greater than 30 μM to the TECK polypeptide.

30 (Previously presented). The method of Claim 1 wherein the antibody or antigen-binding fragment exhibits a Kd greater than 10 μM to the TECK polypeptide.

31 (Previously presented). The method of Claim 1 wherein the antibody or antigen-binding fragment exhibits a Kd greater than 3 μM to the TECK polypeptide.

32 (New). The method of claim 1 wherein the antibody or fragment is administered in a pharmaceutical composition comprising a pharmaceutically acceptable carrier.

33 (New). A method for treating Crohn's disease small intestine inflammation, comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antagonist monoclonal antibody that binds specifically to an epitope in a polypeptide which epitope consists of amino acids Gln1 to Leu127 of SEQ ID NO: 4, to said subject.

34 (New). A method for treating inflammatory bowel disease small intestine inflammation, comprising administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antagonist monoclonal antibody that binds specifically to an epitope in a polypeptide which epitope consists of amino acids Gln1 to Leu127 of SEQ ID NO: 4, to said subject.

35 (New). The method of Claim 1 wherein the antibody or fragment is an antibody and the antibody is an anti-idiotypic antibody.

36 (New). The method of Claim 1 wherein the antibody or fragment is recombinant.

37 (New). The method of Claim 1 wherein the antibody or fragment is an antibody and the antibody is a chimeric antibody.

38 (New). The method of Claim 1 wherein the antibody or fragment is an antibody and the antibody is a humanized antibody.